The Covid-19 vaccine challenge trials are officially coming

After nearly a year of public advocacy and often rancorous ethical debate, human challenge trials for Covid-19 vaccines are getting off the ground in London.

The UK government’s Covid-19 Vaccine Taskforce and the contract research firm Open Orphan announced today a £10 million ($13 million) plan to test experimental Covid-19 vaccines in volunteers who are intentionally exposed to the novel coronavirus.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Drug Discovery Today: Modelling the world

With the global prevalence of novel, emergent and largely zoonotic pathogens achieving new historical heights, it is imperative that researchers in the field of infectious disease find ways of modelling interventions that match or exceed traditional drug development

Open Orphan Plc

Open Orphan article published in Drug Discovery Today

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organization (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced an article submission has been published in Drug Discovery Today,

Open Orphan Plc

Codagenix and SII begin dosing in Phase I Covid-19 vaccine trial

Biotechnology firm Codagenix and Serum Institute of India (SII) have dosed the first patient in Phase I clinical trial of a single-dose, intranasal Covid-19 vaccine, COVI-VAC. Developed with Codagenix’s Synthetic Attenuated Virus Engineering (SAVE) platform, the vaccine can

Open Orphan Plc

Nasal Covid vaccine can be potential game-changer

Public health experts believe that intranasal vaccines for coronavirus, administered through nose rather than muscles, can be a potential gamechanger in Indias fight against the coronavirus pandemic. The nasal vaccine is different from two intramuscular vaccines which recently